Literature DB >> 15793150

Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults.

Jong Hwa Lee1, Ji-Hyun Shin, Im Hwan Roe, Seung Ghyu Sohn, Jung Hun Lee, Geun Ho Kang, Han-Ki Lee, Byeong Chul Jeong, Sang Hee Lee.   

Abstract

The outcome of Helicobacter pylori infection was analyzed in 114 dyspeptic patients treated with triple-drug therapy including clarithromycin. Clarithromycin resistance (in 20.2% of our isolates) was mainly caused by an A2142G mutation in the 23S rRNA gene of H. pylori. H. pylori eradication was obtained in all patients with clarithromycin-susceptible isolates but not in any patients with clarithromycin-resistant isolates (P = 0.0001). Therefore, it would be useful to conduct H. pylori antimicrobial susceptibility testing of the first gastric biopsy culture before choosing the first three drugs for therapy of infected patients.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15793150      PMCID： PMC1068646          DOI： 10.1128/AAC.49.4.1600-1603.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study.

Authors:  L J van Doorn; Y Glupczynski; J G Kusters; F Mégraud; P Midolo; N Maggi-Solcà; D M Queiroz; N Nouhan; E Stet; W G Quint
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Clarithromycin resistance and eradication of Helicobacter pylori in children.

Authors:  N Kalach; P H Benhamou; F Campeotto; M Bergeret; C Dupont; J Raymond
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands.

Authors:  Y J Debets-Ossenkopp; A J Herscheid; R G Pot; E J Kuipers; J G Kusters; C M Vandenbroucke-Grauls
Journal:  J Antimicrob Chemother       Date:  1999-04       Impact factor: 5.790

4.  New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates.

Authors:  Carla Fontana; Marco Favaro; Silvia Minelli; Anna Angela Criscuolo; Antonio Pietroiusti; Alberto Galante; Cartesio Favalli
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 5.  Antibiotic-resistant H. pylori infection and its treatment.

Authors:  D Y Graham; W A Qureshi
Journal:  Curr Pharm Des       Date:  2000-10       Impact factor: 3.116

6.  Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer.

Authors:  A Pilotto; M Rassu; G Leandro; M Franceschi; F Di Mario
Journal:  Dig Liver Dis       Date:  2000-12       Impact factor: 4.088

7.  Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication.

Authors:  S Toracchio; L Cellini; E Di Campli; G Cappello; M G Malatesta; A Ferri; A F Ciccaglione; L Grossi; L Marzio
Journal:  Aliment Pharmacol Ther       Date:  2000-12       Impact factor: 8.171

8.  Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach.

Authors:  M P Dore; G Leandro; G Realdi; A R Sepulveda; D Y Graham
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

9.  Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002.

Authors:  S Toracchio; L Marzio
Journal:  Dig Liver Dis       Date:  2003-08       Impact factor: 4.088

10.  Quantitative detection for low levels of Helicobacter pylori infection in experimentally infected mice by real-time PCR.

Authors:  Michał Mikula; Artur Dzwonek; Katarzyna Jagusztyn-Krynicka; Jerzy Ostrowski
Journal:  J Microbiol Methods       Date:  2003-11       Impact factor: 2.363
View more
  16 in total

1.  Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies.

Authors:  Jyh-Ming Liou; Chi-Yang Chang; Wang-Huei Sheng; Yu-Chi Wang; Mei-Jyh Chen; Yi-Chia Lee; Hsu-Wei Hung; Hung Chian; San-Chun Chang; Ming-Shiang Wu; Jaw-Town Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

2.  Characterisation of the genes encoding resistance to metronidazole (rdxA and frxA) and clarithromycin (the 23S-rRNA genes) in South African isolates of Helicobacter pylori.

Authors:  N F Tanih; L M Ndip; R N Ndip
Journal:  Ann Trop Med Parasitol       Date:  2011-04

3.  Incidence of Helicobacter felis and the effect of coinfection with Helicobacter pylori on the gastric mucosa in the African population.

Authors:  E Lekunze Fritz; Tomas Slavik; Wayne Delport; Brenda Olivier; Schalk W van der Merwe
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

4.  Incidence of Helicobacter pylori infection and their clarithromycin-resistant strains in otitis media with effusion regarding phenotypic and genotypic studies.

Authors:  Nahla A Melake; Ghada H Shaker; Magdy A Salama
Journal:  Saudi Pharm J       Date:  2012-03-03       Impact factor: 4.330

5.  Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005.

Authors:  Intetsu Kobayashi; Kazunari Murakami; Mototsugu Kato; Seiichi Kato; Takeshi Azuma; Shin'ichi Takahashi; Naomi Uemura; Tsutomu Katsuyama; Yoshihiro Fukuda; Ken Haruma; Masaru Nasu; Toshio Fujioka
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

Review 6.  Therapeutic management of recurrent peptic ulcer disease.

Authors:  Raymond S Tang; Francis K L Chan
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

7.  Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.

Authors:  Ji Hyun Lim; Dong Ho Lee; Seong Tae Lee; Nayoung Kim; Young Soo Park; Cheol Min Shin; In Sung Song
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

8.  Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.

Authors:  Seong Tae Lee; Dong Ho Lee; Ji Hyun Lim; Nayoung Kim; Young Soo Park; Cheol Min Shin; Hyun Jin Jo; In Sung Song
Journal:  Gut Liver       Date:  2015-07       Impact factor: 4.519

9.  Low Helicobacter pylori primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil.

Authors:  Rodrigo Buzinaro Suzuki; Rodrigo Augusto Basso Lopes; George Arouche da Câmara Lopes; Tin Hung Ho; Márcia Aparecida Sperança
Journal:  BMC Gastroenterol       Date:  2013-12-04       Impact factor: 3.067

10.  Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur.

Authors:  Xinsheng Teh; Yalda Khosravi; Woon Ching Lee; Alex Hwong Ruey Leow; Mun Fai Loke; Jamuna Vadivelu; Khean Lee Goh
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.